- ►diabetesjournals.org MA Nauck, B Baller, JJ Meier - Diabetes, 2004 - Am Diabetes Assoc The incretin effect denominates the phenomenon that oral glucose elicits a
higher insulin response than does intravenous glucose. The two hormones
responsible for the incretin effect, glucose-dependent insulinotropic ... Cited by 61 - Related articles - BL Direct - All 5 versions
MA Nauck, A El-Ouaghlidi, B Gabrys, K … - Regulatory peptides, 2004 - Elsevier Aims/Hypothesis: Since insulin secretion in response to exogenous gastric
inhibitory polypeptide (GIP) is diminished not only in patients with type 2
diabetes, but also in their normal glucose-tolerant first-degree relatives, ... Cited by 33 - Related articles - All 3 versions
- ►physiology.org JJ Meier, O Goetze, J Anstipp, D Hagemann, … - American Journal of Physiology- Endocrinology And …, 2004 - Am Physiological Soc The insulinotropic gut hormone gastric inhibitory polypeptide (GIP) has been
demonstrated to inhibit gastric acid secretion and was proposed to possess
"enterogastrone" activity. GIP effects on gastric emptying have not yet ... Cited by 56 - Related articles - BL Direct - All 4 versions
JJ Meier, B Gallwitz, N Siepmann, JJ Holst, … - Diabetologia, 2003 - Springer Aims/hypothesis. In the isolated perfused pancreas, gastric inhibitory
polypeptide (GIP) has been shown to enhance glucagon secretion at basal glucose
con- centrations, but in healthy humans no glucagonotropic effect of GIP ... Cited by 60 - Related articles - BL Direct - All 3 versions
JJ Meier, MA Nauck - Current Diabetes Reports, 2006 - Springer The incretin hormones gastric inhibitory polypeptide (GIP) and glucagon-like
peptide 1 (GLP-1) are released in response to nutrient ingestion and potentiate
glucose- stimulated insulin secretion from pancreatic β cells. The ... Cited by 20 - Related articles - BL Direct - All 2 versions
T Krarup, N Saurbrey, AJ Moody, C Kühl, S … - Metabolism: clinical and experimental, 1987 - ncbi.nlm.nih.gov The effect of highly purified natural porcine GIP on C-peptide release was
examined in six type I (insulin-dependent) diabetics (IDD) with residual
beta-cell function, six type II non-insulin-dependent) diabetics (NIDD), ... Cited by 41 - Related articles - All 3 versions
JJ Meier, B Gallwitz, B Kask, CF Deacon, JJ … - Diabetes, 2004 - Am Diabetes Assoc A reduced insulinotropic effect of gastric inhibitory polypeptide (GIP) is a
characteristic of patients with type 2 diabetes. It was the aim of this study to
determine the response of insulin secretion to different GIP doses ... Cited by 41 - Related articles - BL Direct - All 4 versions
T Vilsbøll, T Krarup, S Madsbad, J Holst - Diabetologia, 2002 - Springer Aims/hypothesis. Glucagon-like-peptide-1 (GLP-1) is strongly insulinotropic in
patients with Type II (non- insulin-dependent) diabetes mellitus, whereas glu-
cose-dependent insulinotropic polypeptide (GIP) is less effective. Our ... Cited by 135 - Related articles - BL Direct - All 4 versions
CF Deacon - Hormone and Metabolic Research, 2004 - thieme-connect.com The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) are secreted from the intestinal K- and L-cells,
respectively, but are immediately subject to rapid degradation. GLP-1 is ... Cited by 48 - Related articles - All 7 versions
[CITATION] No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 …
